| Ytd | -60.37% | |
| 1y | -86.76% |
| Open | 2.96 | Prev Close | 3.02 | Low | 2.85 | High | 2.99 | Mkt Cap | 13.56M |
| Vol | 18.79K | Avg Vol | 329.53K | EPS | -8.25 | P/E | -0.37 | Forward P/E | -0.41 |
| Beta | 0.43 | Short Ratio | 0.09 | Inst. Own | 16.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 4.66 | 200-d Avg | 6.48 | 1yr Est | 169.00 |
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION T
Quantum BioPharma stock momentum surges as MS study hits 50% enrollment and early PET imaging data s
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(0.71) per share which beat the analys
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the &#
https://www.globenewswire.com/news-release/2026/03/11/3254229/0/en/Quantum-BioPharma-Provides-Corpor